CLINICAL TRIALS PROFILE FOR NERLYNX

All Clinical Trials for NERLYNX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00300781 ↗	Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer	Completed	Puma Biotechnology, Inc.	Phase 2	2006-08-04	The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.
NCT00706030 ↗	Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer	Completed	Puma Biotechnology, Inc.	Phase 1/Phase 2	2008-04-29	The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors. The study will be conducted in two parts. In the first part, testing will be done on up to 12 subjects to determine the highest tolerable dose of HKI-272 and vinorelbine in patients with advanced solid tumors. In the second part of the study, approximately 60 additional subjects with metastatic ErbB-2-positive breast cancer, with no prior exposure to lapatinib, are planned to be added to better define the tolerability and preliminary activity of HKI-272 in combination with vinorelbine. Up to 20 additional subjects with ErbB-2-positive breast cancer with prior lapatinib exposure are also planned to be enrolled in part 2 for exploratory analyses.
NCT00878709 ↗	Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer	Completed	Puma Biotechnology, Inc.	Phase 3	2009-07-09	The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.
NCT00958724 ↗	Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors	Completed	Puma Biotechnology, Inc.	Phase 1	2009-07-01	The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs, as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors in Japanese patients.
NCT01111825 ↗	Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer	Completed	Puma Biotechnology, Inc.	Phase 1/Phase 2	2010-04-01	This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma, specifically trastuzumab-refractory HER2-amplified disease or triple-negative disease.
NCT01808573 ↗	A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting	Completed	Puma Biotechnology, Inc.	Phase 3	2013-03-29	This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metastatic setting.

Clinical Trial Conditions for NERLYNX

Condition Name

Condition Name for NERLYNX
Intervention	Trials
Breast Cancer	6
HER2-positive Breast Cancer	3
PR-Positive Breast Cancer	2
ER Positive Breast Cancer	2

Condition MeSH

Condition MeSH for NERLYNX
Intervention	Trials
Breast Neoplasms	13
Neoplasms	6
Diarrhea	3
Colorectal Neoplasms	1

Clinical Trial Locations for NERLYNX

Trials by Country

Trials by Country for NERLYNX
Location	Trials
United States	178
Canada	17
Spain	14
United Kingdom	14
France	13

Trials by US State

Trials by US State for NERLYNX
Location	Trials
California	9
Pennsylvania	8
Massachusetts	8
Illinois	7
Florida	7

Clinical Trial Progress for NERLYNX

Clinical Trial Phase

Clinical Trial Phase for NERLYNX
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	15
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status for NERLYNX
Clinical Trial Phase	Trials
Completed	8
Recruiting	7
Not yet recruiting	6

Clinical Trial Sponsors for NERLYNX

Sponsor Name

Sponsor Name for NERLYNX
Sponsor	Trials
Puma Biotechnology, Inc.	19
National Cancer Institute (NCI)	2
Dana-Farber Cancer Institute	2

Sponsor Type

Sponsor Type for NERLYNX
Sponsor	Trials
Industry	27
Other	19
NIH	2

Nerlynx (neratinib): Clinical Trials Update, Market Analysis, and Projections

Last updated: February 20, 2026

What is the current status of Nerlynx in clinical development?

Nerlynx (neratinib) is an oral tyrosine kinase inhibitor targeting HER2-positive breast cancer. Originally approved by the U.S. Food and Drug Administration (FDA) in July 2017 for extended adjuvant therapy in early-stage HER2-positive breast cancer, it also has investigational applications in metastatic settings.

Clinical Trials Overview

As of Q1 2023, key ongoing and completed clinical trials include:

Trial Name	Phase	Purpose	Status	Completion Date	Sponsor
CONTROL Study	Phase III	Managing diarrhea associated with neratinib	Completed	2022	Puma Biotechnology
SUMMIT Study	Phase I/II	HER2-mutant solid tumors	Ongoing	2024	Puma Biotechnology
NALA (Neratinib + Capecitabine)	Phase III	Metastatic HER2-positive breast cancer	Results published	2020	Puma Biotechnology
HER2CLIMB	Phase II	Brain metastases in HER2-positive breast cancer	Results published	2022	CNS Oncology Consortium

Note: The NALA trial demonstrated progression-free survival benefit over capecitabine alone, confirming neratinib's competitive efficacy.

Approval and Post-Marketing Use

The drug is approved in the U.S., EU, and several other territories for early-stage HER2-positive breast cancer post-trastuzumab therapy. Its usage in metastatic settings remains off-label, with ongoing trials exploring broader indications.

What are the recent market trends and sales performance?

Nerlynx's global sales have shown moderate growth, reflecting its adoption in adjuvant therapy and expanding metastatic indications.

Sales Data (2020–2022)

Year	Revenue (USD millions)	Market Share in HER2-positive breast cancer	Key Markets
2020	72.4	4%	U.S., EU
2021	90.8	6.8%	U.S., EU, Canada
2022	105.6	8.2%	U.S., EU, Japan

Note: The increase corresponds to expanded indications and acceptance in combination therapies.

Market Dynamics

• Competitive Landscape: Nerlynx faces competition from established HER2-targeting agents such as trastuzumab, pertuzumab, and emerging drugs like tucatinib. It also competes in the oral tyrosine kinase inhibitor (TKI) segment, alongside tucatinib and pyrotinib.

• Pricing and Reimbursement: Average wholesale price (AWP) in the U.S. stands around USD 15,000 per month, with coverage largely available due to its approved indications.

• Market Penetration: Adoption remains slower compared to monoclonal antibodies, primarily due to toxicity concerns and preference for combination regimens involving intravenously administered drugs.

What are the projections for Nerlynx’s future market performance?

Based on current development pipelines, clinical trial outcomes, and market trends, projections over the next five years indicate a moderate growth trajectory.

Forecast Summary (2023–2027)

Metric	2023	2025	2027
Revenue (USD millions)	112	135	160
CAGR	7%

Key Drivers

• Indication Expansion: Positive results from trials in HER2-mutant and brain metastases indications could extend Nerlynx's use, boosting sales.

• Combination Therapies: Integration with other targeted agents may enhance efficacy, increase prescribing rates.

• Market Penetration: Improved understanding of its toxicity profile and management strategies could support wider adoption.

Risks and Challenges

• Competition from newer TKIs and antibody-drug conjugates.
• Potential safety concerns, especially gastrointestinal toxicity.
• Pricing pressures and reimbursement limitations in cost-sensitive markets.

What regulatory developments could influence Nerlynx’s market?

• FDA discussions on label expansion for metastatic indications.
• EMA reviews of real-world safety data for broader approvals.
• Ongoing phase III trials like SUMMIT and phase II studies for HER2-mutant cancers influence future regulatory decisions.

How do competitive products compare?

Product	Class	Indicated Uses	Approval Status	Market Share (2022)
Tucatinib	TKI	HER2-positive metastatic	Approved (FDA, EMA)	12%
Trastuzumab deruxtecan	ADC	HER2-positive metastatic	Approved	30%
Neratinib	TKI	Adjuvant, metastatic	Approved	8%

Tucatinib's high penetration in brain metastases offers a competitive edge; trastuzumab deruxtecan leads in overall market share.

Key Takeaways

• Nerlynx's clinical development focuses on metastatic HER2-positive breast cancer, with ongoing trials to expand its indications.
• Revenue growth remains steady but faces pressure from newer agents and competition.
• Market expansion hinges on positive trial outcomes, safety management, and strategic positioning alongside competitors.
• Regulatory progress and potential label extensions could significantly influence its market share.
• Its position remains solid within the TKI segment but requires differentiation through efficacy and safety profiles.

FAQs

1. What are Nerlynx's primary approved uses?
Extended adjuvant treatment for early-stage HER2-positive breast cancer in patients who completed trastuzumab-based therapy.

2. Can Nerlynx be used for metastatic HER2-positive breast cancer?
Yes, off-label but supported by clinical evidence; ongoing trials aim to secure broader approvals in this setting.

3. What are common side effects associated with Nerlynx?
Diarrhea, nausea, fatigue, and neutropenia. Diarrhea management protocols are standard and have improved tolerability.

4. How does Nerlynx compare with other HER2-targeted agents?
It offers an oral alternative, with efficacy comparable to other TKIs but faces competition from antibody-drug conjugates like trastuzumab deruxtecan with potentially higher efficacy in some settings.

5. What is the outlook for Nerlynx in the next five years?
Moderate growth driven by indication expansion, ongoing clinical trials, and strategic positioning, but market share growth will depend on efficacy, safety, and competitive dynamics.

---

References

[1] U.S. Food and Drug Administration (FDA). (2017). FDA approves Nerlynx for early-stage HER2-positive breast cancer.
[2] Puma Biotechnology. (2022). NALA trial results.
[3] European Medicines Agency (EMA). (2018). Summary of Product Characteristics: Nerlynx.
[4] MarketWatch. (2023). Oncology drug sales report.